Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shot up 4.5% during trading on Monday . The company traded as high as $6.68 and last traded at $6.64. 6,581,735 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 10,331,976 shares. The stock had previously closed at $6.35.
Analyst Ratings Changes
A number of research firms have issued reports on RXRX. Needham & Company LLC reissued a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Leerink Partners decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $8.25.
Get Our Latest Report on RXRX
Recursion Pharmaceuticals Stock Up 1.5 %
The firm has a 50-day moving average price of $7.47 and a two-hundred day moving average price of $7.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of -4.29 and a beta of 0.85.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The business had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's quarterly revenue was down 57.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.42) EPS. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Recursion Pharmaceuticals
A number of large investors have recently made changes to their positions in RXRX. Softbank Group CORP. bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth approximately $99,152,000. Novo Holdings A S bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth approximately $68,375,000. Vanguard Group Inc. increased its stake in Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after acquiring an additional 9,737,196 shares during the period. State Street Corp increased its stake in Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after acquiring an additional 4,120,685 shares during the period. Finally, Norges Bank bought a new position in Recursion Pharmaceuticals during the 4th quarter worth $23,429,000. Institutional investors own 89.06% of the company's stock.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
